QIAGEN (QGEN) and Incyte (INCY) announced a new global collaboration to develop a novel diagnostic panel to support Incyte’s extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms, a group of rare blood cancers, including Incyte’s monoclonal antibody INCA033989, targeting mutant calreticulin, which is being developed in myelofibrosis and essential thrombocythemia. Under the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the next-generation sequencing technology and the Illumina NextSeq 550Dx platform as part of QIAGEN’s partnership with Illumina (ILMN) to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide. QIAGEN will support regulatory submission processes and market access activities across the United States, European Union and Asia-Pacific regions.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN: